5,6-亚甲基二氧基-1-四酮 | 84854-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 5,6-亚甲基二氧基-1-四酮
• 英文名称: 5,6-methylenedioxy-3,4-dihydro-1(2H)-naphthalenone
• 英文别名: 5,6-(methylenedioxy)-1-tetralone；5,6-Methylenedioxy-1-tetralone；5,6-methylenedioxy-1,2,3,4tetrahydro-1-naphthalenone；8,9-dihydro-7H-benzo[g][1,3]benzodioxol-6-one
• CAS: 84854-57-9
• 化学式: C₁₁H₁₀O₃
• mdl: MFCD08234374
• 分子量: 190.199
• InChiKey: OJBDSNGDZANUCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  74-75 °C
• 沸点：
  354.7±42.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  5,6-亚甲基二氧基-1-四酮 在 sodium tetrahydroborate 、 三氯化铝 、 对甲苯磺酸 作用下， 以 乙醇 、 甲苯 、 苯 为溶剂， 反应 3.25h， 生成 1-cyano-5,6-(methylenedioxy)tetralin
  参考文献：
  名称：

  Conformationally defined adrenergic agents. 3. Modifications to the carbocyclic ring of 5,6-dihydroxy-1-(2-imidazolinyl)tetralin: improved separation of .alpha.1 and .alpha.2 adrenergic activities

  摘要：

  A series of modifications to positions 1, 2, and 4 of the tetralin ring of 5,6-dihydroxy-1-(2-imidazolinyl)tetralin (1, A-54741) succeeded in improving the separation of the potent alpha 1 and alpha 2 adrenergic agonism observed for the parent compound 1. In particular 5,6-dihydroxy-4,4-dimethyl-1-(2-imidazolinyl)tetralin (7) was found to be a specific alpha 1 adrenergic agonist, and 7,8-dihydroxy-4-(2-imidazolinyl)chroman (2) was found to have improved alpha 2 adrenergic agonistic selectivity relative to the parent compound 1.

  DOI：

  10.1021/jm00158a016
• 作为产物：
  描述：

  4-溴-1,3-苯并二恶唑 在 palladium on activated charcoal 盐酸 、 四(三苯基膦)钯 、 氢气 、 三氟乙酸酐 作用下， 反应 12.25h， 生成 5,6-亚甲基二氧基-1-四酮
  参考文献：
  名称：

  Tributylstannyl 4-tributylstannylbut-3-enoate: a useful C-4 homologating agent. Application to the synthesis of aryl iodolactones

  摘要：

  Tributylstannyl 4-tributylstannylbut-3-enoate, readily prepared by radical hydrostannation, is used for the transfer of a but-3-enoic acid synthon. Some of the potentialities of this synthon are established by the synthesis of aryl iodolactones or tetralones (one of them is a key intermediate for ABT-200 synthesis). Copyright (C) 1996 Published by Elsevier Science Ltd

  DOI：

  10.1016/0040-4039(96)01725-x

文献信息

• Synthesis and biological activities of 3-aminomethyl-1,2-dihydronaphthalene derivatives.
  作者：KATSUMI ITOH、AKIO MIYAKE、MASAO TANABE、MINORU HIRATA、YOSHIKAZU OKA

  DOI：10.1248/cpb.31.2006

  日期：——

  A series of 3-aminomethyl-1, 2-dihydronaphthalene derivatives (6-22) was prepared from the corresponding 3, 4-dihydro-1 (2H)-naphthalenone derivatives (24a-q) in three steps, namely the Mannich reaction, reduction of the carbonyl group with sodium borohydride, and dehydration with ethanolic hydrogen chloride. Compounds 6-22 and several related analogs (23, 27-30) were tested for vasodilating and antihypertensive activities. Potent cerebral vasodilating and antihypertensive activities were exhibited by 1-benzhydryl-4-(7-disubstituted amino-1, 2-dihydro-3-naphthyl) methylpiperazines (16, 18 and 19).

  一系列3-氨基甲基-1,2-二氢萘衍生物（6-22）通过三步反应从相应的3,4-二氢-1(2H)-萘酚酮衍生物（24a-q）制备得到，这三步反应分别是曼尼希反应、用硼氢化钠还原羰基和用乙醇氢氯酸脱水。化合物6-22及其相关类似物（23, 27-30）被测试了血管舒张和抗高血压活性。1-二苯甲基-4-(7-二取代氨基-1,2-二氢-3-萘基)甲基哌嗪（16,18和19）展现了强大的脑部血管舒张和抗高血压活性。
• 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US05128362A1

  公开（公告）日：1992-07-07

  The present invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is selected from hydrogen, halo, lower alkyl, lower alkoxy, or thioalkoxy; and R.sub.2 is lower alkoxy; or R.sub.1 and R.sub.2 together form a methylenedioxy or ethylenedioxy ring; R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, (lower alkyl)amino, (lower alkylsulfonyl)amino, and halo; and R.sub.7 is selected from the group consisting of 2- or 3-thienyl, 2- or 3-furyl, and ##STR2## where R.sub.13 and R.sub.14 are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower alkyl, lower alkoxy, lower alkylthio, methylenedioxy, or ethylenedioxy. The compounds of the present invention selectively inhibit .alpha..sub.2 -adrenergic receptors as well as inhibit the uptake of biogenic amines and are thus useful in the treatment of certain cardiovascular and psychiatric disorders.

  本发明提供了以下结构的化合物##STR1##或其药学上可接受的盐，其中R.sub.1从氢、卤素、较低的烷基、较低的烷氧基或硫代烷氧基中选择；而R.sub.2是较低的烷氧基；或者R.sub.1和R.sub.2一起形成一个亚甲二氧基或乙二氧基环；R.sub.3和R.sub.4独立地从氢、羟基、较低的烷基、较低的烷氧基、较低的烷硫基、(较低的烷基)氨基、(较低的烷基磺酰基)氨基和卤素中选择；而R.sub.7从2-或3-噻吩基、2-或3-呋喃基和##STR2##中选择，其中R.sub.13和R.sub.14独立地从氢、羟基、卤素、氨基、较低的烷基、较低的烷氧基、较低的烷硫基、亚甲二氧基或乙二氧基中选择。本发明的化合物选择性地抑制α2-肾上腺素受体，并抑制生物胺的摄取，因此在治疗某些心血管和精神疾病方面具有用处。
• Aminoalkyl dihydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US04473586A1

  公开（公告）日：1984-09-25

  Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.10 are independently selected from hydrogen, hydroxy, methoxy, loweralkyl of 1 to 4 carbon atoms, or halo, or R.sub.9 and R.sub.10 can be taken together to form a methylenedioxy or ethylenedioxy bridge; or 1,4-benzodioxan of the formula ##STR5## wherein q is 1, 2 or 3, and R.sub.11 is hydrogen, methoxy, or halo; or R.sub.3 and R.sub.4 can be taken together to form a piperazino, piperidino or morpholino moiety; and the pharmaceutically acceptable salts thereof. Also disclosed are novel intermediates useful in the preparation of these compounds.

  本公开涉及由下式表示的1-氨基烷基-3,4-二氢萘烯衍生物，其中n为1或2；R、R.sub.1和R.sub.2分别选自氢、羟基、1至3个碳原子的低烷氧基、1至3个碳原子的低烯氧基、硫甲基、卤素，或下式中的其中一种：其中R.sub.5和R.sub.6分别选自氢、1至4个碳原子的低酰基或下式的磺酰基：其中R.sub.7为1至4个碳原子的低烷基；或R和R.sub.1，或R.sub.1和R.sub.2可结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须为氢以外的其他基团；R.sub.3和R.sub.4分别选自氢、1至4个碳原子的低烷基、1至4个碳原子的卤素取代的低烷基、下式的芳基烷基：其中m为0、1或2，p为0或1，R.sub.8为氢或1至4个碳原子的低烷基，R.sub.9和R.sub.10分别选自氢、羟基、甲氧基、1至4个碳原子的低烷基或卤素，或R.sub.9和R.sub.10可结合形成亚甲二氧桥或乙烯二氧桥；或下式的1,4-苯二氧杂环己烷：其中q为1、2或3，R.sub.11为氢、甲氧基或卤素；或R.sub.3和R.sub.4可结合形成哌嗪基、哌啶基或吗啉基；以及其药用盐。还公开了用于制备这些化合物的新型中间体。
• Synthesis of 1‐Tetralone Derivatives Using a Stille Cross Coupling/Friedel Crafts Acylation Sequence
  作者：Johnny Vercouillie、Mohamed Abarbri、Jean‐Luc Parrain、Alain Duchêne、Jérôme Thibonnet

  DOI：10.1081/scc-200032474

  日期：2004.1.1

  Abstract An efficient method of synthesis of 1‐tetralones has been achieved featuring a Stille cross‐coupling reaction as the key step.

  摘要 以Stille交叉偶联反应为关键步骤，实现了一种有效的1-四氢萘酮合成方法。
• Synthesis of 5,6-methylenedioxy-1-tetralone. An aryl grignard approach from guaiacol
  作者：Russell C. Klix、Michael H. Cain、Ashok V. Bhatia

  DOI：10.1016/0040-4039(95)01343-g

  日期：1995.9

  A convenient synthesis of 5,6-methylenedioxy-1-tetralone (1) is described. The main features of this synthesis are the formation of 6 via a Grignard reaction using succinic anhydride followed by selective reduction and Friedel-Crafts cyclization to generate the desired tetralone 1.

  描述了5，6-亚甲基二氧基-1-四氢萘酮（1）的方便合成。该合成的主要特征是使用丁二酸酐通过格氏反应形成6，然后进行选择性还原和Friedel-Crafts环化反应生成所需的四氢萘酮1。